697 related articles for article (PubMed ID: 26163610)
41. [Clinical significance of serum high-mobility group box 1 detection in esophageal squamous cell carcinoma].
Chen CG; Cui L; Tang P; Yu ZT
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):838-41. PubMed ID: 24061989
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic value of bronchoalveolar lavage fluid and serum tumor markers for lung cancer.
Wang H; Zhang X; Liu X; Liu K; Li Y; Xu H
J Cancer Res Ther; 2016; 12(1):355-8. PubMed ID: 27072263
[TBL] [Abstract][Full Text] [Related]
43. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
44. Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients.
Sone K; Oguri T; Ito K; Kitamura Y; Inoue Y; Takeuchi A; Fukuda S; Takakuwa O; Maeno K; Asano T; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
Anticancer Res; 2017 Sep; 37(9):5125-5131. PubMed ID: 28870944
[TBL] [Abstract][Full Text] [Related]
45. The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer.
Liu L; Teng J; Zhang L; Cong P; Yao Y; Sun G; Liu Z; Yu T; Liu M
Biomed Res Int; 2017; 2017():2013989. PubMed ID: 28607926
[TBL] [Abstract][Full Text] [Related]
46. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
[TBL] [Abstract][Full Text] [Related]
47. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?
Li M; Zhang Y; Jiang L; Li Y; Li G; Zhou J; Yang C; Li X; Qu W; Chen Y; Chen Q; Wang S; Xing J; Huang H
Neoplasma; 2022 May; 69(3):729-740. PubMed ID: 35471981
[TBL] [Abstract][Full Text] [Related]
48. [Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
Wang Q; Zheng H; Hu F; Zhang H; Hu Y; Li J; Zhang T; Liu Z; Lu B; Hu A; Li B
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):550-8. PubMed ID: 27561807
[TBL] [Abstract][Full Text] [Related]
49. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
50. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
51. Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer.
Gaspar MJ; Diez M; Rodriguez A; Ratia T; Martin Duce A; Galvan M; Granell J; Coca C
Anticancer Res; 2003; 23(4):3427-32. PubMed ID: 12926084
[TBL] [Abstract][Full Text] [Related]
52. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
[TBL] [Abstract][Full Text] [Related]
53. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
[TBL] [Abstract][Full Text] [Related]
54. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
55. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples.
Thomas DS; Fourkala EO; Apostolidou S; Gunu R; Ryan A; Jacobs I; Menon U; Alderton W; Gentry-Maharaj A; Timms JF
Br J Cancer; 2015 Jul; 113(2):268-74. PubMed ID: 26035703
[TBL] [Abstract][Full Text] [Related]
57. Serum CEA, CA125, and SCC antigens and tumor recurrence in resectable non-small cell lung cancer.
Diez M; Gomez A; Hernando F; Ortega MD; Maestro ML; Torres A; Mugüerza JM; Gutierrez A; Granell J; Balibrea JL
Int J Biol Markers; 1995; 10(1):5-10. PubMed ID: 7629428
[TBL] [Abstract][Full Text] [Related]
58. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
59. [Tumor marker in primary lung cancer].
Sugio K; Sugaya M; Hanagiri T; Yasumoto K
J UOEH; 2004 Dec; 26(4):473-9. PubMed ID: 15624359
[TBL] [Abstract][Full Text] [Related]
60. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
